PORT WASHINGTON, N.Y., April 04, 2013 - Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, today confirmed plans for a state-of–the-art Life Sciences Centre of Excellence at its new Harbourgate site in Portsmouth in the United Kingdom (UK). The Centre of Excellence (COE), which will open in mid 2013, will offer a full suite of capabilities including cell culture, purification, analytical solutions, protein characterization and microbiological tools. This latest COE will complement recently announced Life Sciences Centres in the United States (Westborough, Massachusetts and Menlo Park, California) as well as investments previously announced in China, Singapore and India.
“The announcement of Pall’s new Portsmouth Centre of Excellence provides another example of our commitment to meeting the diverse needs of our Life Sciences customers across the globe,” said Yves Baratelli, president, Pall Life Sciences. "Portsmouth represents an important Life Sciences hub for Pall. By upgrading and expanding our capabilities at the site, we are not only enhancing our ability to service our customers, but also creating a multi-disciplinary and responsive environment in which Pall scientists and engineers can thrive and innovate.”
The new Portsmouth COE will include a dedicated 4000 m² scientific area with a connected walkway to another recently opened facility that houses an additional 2000 m² for Life Sciences technical support and training, R&D engineering and product management. Manufacturing and test areas will remain at the current Walton Road site in Portsmouth.
In addition to customer service support, COE offerings will include the development, testing and validation of a wide range of products that now form part of Pall's portfolio. There also will be an extensive range of scale-up technology on hand for applying industry-leading standards to match demands for fully representative and rapid drug development.
About Pall Life Sciences
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall technologies are also used in clinical institutions and the food and beverage industries.
About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.
Corporate Director Public Relations email@example.com
Follow us on Twitter @pallcorporation